These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 17504227)

  • 1. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
    Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
    Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
    Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
    Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
    Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
    Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
    Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
    Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
    Park EJ; Choi KS; Yoo YH; Kwon TK
    Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
    Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
    Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
    Tazzari PL; Tabellini G; Ricci F; Papa V; Bortul R; Chiarini F; Evangelisti C; Martinelli G; Bontadini A; Cocco L; McCubrey JA; Martelli AM
    Cancer Res; 2008 Nov; 68(22):9394-403. PubMed ID: 19010914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
    Voltan R; Secchiero P; Corallini F; Zauli G
    Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
    Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
    Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
    Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
    Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
    Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pseudo-caspase FLIP(L) regulates cell fate following p53 activation.
    Lees A; McIntyre AJ; Crawford NT; Falcone F; McCann C; Holohan C; Quinn GP; Roberts JZ; Sessler T; Gallagher PF; Gregg GMA; McAllister K; McLaughlin KM; Allen WL; Egan LJ; Ryan AE; Labonte-Wilson MJ; Dunne PD; Wappett M; Coyle VM; Johnston PG; Kerr EM; Longley DB; McDade SS
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17808-17819. PubMed ID: 32661168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.